C. Lance Cowey - Concepedia

Author

C. Lance Cowey

Also Known As

C L Cowey, C Lance Cowey, C. Lance Cowey, C.-L. Cowey, C.L. Cowey, Charles Cowey, Charles L. Cowey, Charles Lance Cowey, Cowey, C Lance, Hickey, M. M.

111

Publications

21.5K

Citations

H-Index

Concepts

All Affiliations

Texas Oncology University of Colorado Denver Bristol-Myers Squibb (United States)Dana-Farber Cancer Institute University of Colorado Cancer Center

About

C. Lance Cowey is an author at Texas Oncology specializing in oncology, medicine, and cancer therapeutics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	22	28	4K
2	Health Sciences	5	5	275
3	Engineering	2	2	22
4	Natural Sciences	2	2	22
5	Public Health	2	2	56

C. Lance Cowey

Publications

21.4K

Citations

H-Index

Page 1

	Year	Citations
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma James Larkin, Vanna Chiarion‐Sileni, René González, New England Journal of Medicine	2015	8K
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma Jedd D. Wolchok, Vanna Chiarion‐Sileni, René González, New England Journal of Medicine	2017	5.3K
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma Jeffrey S. Weber, Mario Mandalà, Michele Del Vecchio, New England Journal of Medicine	2017	2.1K
Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial F. Stephen Hodi, Vanna Chiarion‐Sileni, René González, The Lancet Oncology MedicineMelanomaClinical TrialsImmune Checkpoint InhibitorDermatology	2018	1.4K
Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study Jeffrey S. Weber, Matteo S. Carlino, Adnan Khattak, The Lancet MedicineMelanomaImmunologyPathologyResected Melanoma	2024	598
Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma Jedd D. Wolchok, Vanna Chiarion‐Sileni, René González, Zurich Open Repository and Archive (University of Zurich)	2022	557
Adjuvant nivolumab versus ipilimumab in resected stage IIIB–C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial Paolo A. Ascierto, Michele Del Vecchio, Mario Mandalà, The Lancet Oncology Checkmate 238Surgical OncologyMedicineMelanomaPathology	2020	505
Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials Dirk Schadendorf, Jedd D. Wolchok, F. Stephen Hodi, Journal of Clinical Oncology Adverse EventsMedicineMelanomaClinical TrialsTreatment Option	2017	438
Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma Jedd D. Wolchok, Vanna Chiarion‐Sileni, Piotr Rutkowski, New England Journal of Medicine	2024	343
Neoadjuvant Clinical Trial With Sorafenib for Patients With Stage II or Higher Renal Cell Carcinoma C. Lance Cowey, Chirag Amin, Raj S. Pruthi, Journal of Clinical Oncology	2010	197

Page 1